Yu‐Tzu Tai

25.9k citations

271 papers · 15.1k indexed · 7 hit papers · h-index 67

Molecular Biology top 0.5%
Hematology top 0.05%
Oncology top 0.2%
Immunology top 0.5%
Genetics top 0.5%

Co-authors: Kenneth C. Anderson Teru Hideshima Nikhil C. Munshi Dharminder Chauhan Paul G. Richardson Noopur Raje Klaus Podar Steven P. Treon
Topics: Multiple Myeloma Research and Treatments (184 papers)Protein Degradation and Inhibitors (51 papers)Peptidase Inhibition and Analysis (40 papers)
Cited by: Hematology Oncology Genetics
Journals: Cell Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States China Italy

In The Last Decade

Yu‐Tzu Tai

265 papers receiving 14.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuropilin Is a Semaphorin III Receptor

1997 1.0k citations Yu‐Tzu Tai et al. profile →
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

2010 746 citations Yu‐Tzu Tai, Kenneth C. Anderson et al. profile →
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 708 citations Teru Hideshima, Dharminder Chauhan et al. Blood profile →
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 575 citations Paul G. Richardson, Yu‐Tzu Tai et al. Blood profile →
Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

2014 375 citations Yu‐Tzu Tai, Paul G. Richardson et al. Blood profile →
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

2021 236 citations Mehmet Samur, Mariateresa Fulciniti et al. profile →

Peers

Countries citing papers authored by Yu‐Tzu Tai

Since Specialization

Citations

This map shows the geographic impact of Yu‐Tzu Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Tzu Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Tzu Tai more than expected).

Fields of papers citing papers by Yu‐Tzu Tai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Tzu Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Tzu Tai. The network helps show where Yu‐Tzu Tai may publish in the future.

Co-authorship network of co-authors of Yu‐Tzu Tai

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Tzu Tai. A scholar is included among the top collaborators of Yu‐Tzu Tai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Tzu Tai. Yu‐Tzu Tai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma 2023 ·Blood ·Subodh Kumar,Srikanth Talluri,(unknown),(unknown),(unknown),Leutz Buon,Shidai Mu,Jialan Shi,(unknown),Yu‐Tzu Tai,Mehmet Samur,Nikhil C. Munshi,Masood A. Shammas	3
2	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression 2021 ·Clinical Cancer Research ·Lijie Xing,Su Wang,Jiye Liu,Tengteng Yu,Hailin Chen,Kenneth Wen,Yuyin Li,Liang Lin,Phillip A. Hsieh,Shih‐Feng Cho,Gang An,Lugui Qiu,Krista Kinneer,Nikhil C. Munshi,Kenneth C. Anderson,Yu‐Tzu Tai	22
3	Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation 2021 ·Blood Cancer Discovery ·Annamaria Gullà,Eugenio Morelli,Mehmet Samur,Cirino Botta,Teru Hideshima,Giada Bianchi,Mariateresa Fulciniti,(unknown),Rao Prabhala,Srikanth Talluri,Kenneth Wen,Yu‐Tzu Tai,Paul G. Richardson,Dharminder Chauhan,Tomasz Sewastianik,Ruben D. Carrasco,Nikhil C. Munshi,Kenneth C. Anderson	92
4	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment 2021 ·Blood Cancer Discovery ·Giada Bianchi,Peter G. Czarnecki,Matthew Ho,Aldo M. Roccaro,Antonio Sacco,Yawara Kawano,Annamaria Gullà,Anıl Aktaş Samur,(unknown),Kenneth Wen,Yu‐Tzu Tai,(unknown),Xinchen Wu,Gulden Camci‐Unal,Matteo Da Vià,Niccolò Bolli,Tomasz Sewastianik,Ruben D. Carrasco,Irene M. Ghobrial,Kenneth C. Anderson	12
5	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a 2020 ·Molecular Cancer Research ·Tengteng Yu,(unknown),Xiaoke Ma,Weiwei Sui,Zhen Yu,Lanting Liu,Lei Zhao,(unknown),Jie Xu,Xiaojing Wei,Wen Zhou,Shuhui Deng,Dehui Zou,Gang An,Yu‐Tzu Tai,Guido Tricot,Kenneth C. Anderson,Lugui Qiu,Fenghuang Zhan,Mu Hao	21
6	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma 2020 ·Leukemia ·Liang Lin,Shih‐Feng Cho,Lijie Xing,Kenneth Wen,Yuyin Li,Tengteng Yu,Phillip A. Hsieh,Hailin Chen,Metin Kurtoğlu,Yi Zhang,Charles A. Stewart,Nikhil C. Munshi,Kenneth C. Anderson,Yu‐Tzu Tai	64
7	Progression signature underlies clonal evolution and dissemination of multiple myeloma 2020 ·Blood ·Yu J. Shen,Yuji Mishima,Jiantao Shi,Romanos Sklavenitis‐Pistofidis,Robert Redd,Michele Moschetta,Salomon Manier,Aldo M. Roccaro,Antonio Sacco,Yu‐Tzu Tai,François Mercier,Yawara Kawano,Nang Kham Su,Brianna Berrios,John G. Doench,David E. Root,Franziska Michor,David T. Scadden,Irene M. Ghobrial	32
8	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma 2019 ·Blood Advances ·Andrea Schmidts,Maria Ormhøj,Bryan D. Choi,Allison Taylor,Amanda A. Bouffard,Irene Scarfò,Rebecca C. Larson,Matthew J. Frigault,Kathleen Gallagher,Ana P. Castaño,Lauren S. Riley,Maria L. Cabral,Angela C. Boroughs,Rubí M.-H. Velasco Cárdenas,Wolfgang W. Schamel,Jing Zhou,Sean Mackay,Yu‐Tzu Tai,Kenneth C. Anderson,Marcela V. Maus	85
9	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab 2018 ·Molecular Cancer Therapeutics ·Ahmed T. Kurdi,Siobhan Glavey,Natalie Bezman,(unknown),Jennifer L. Guerriero,Salomon Manier,Michele Moschetta,Yuji Mishima,Aldo M. Roccaro,Alexandre Detappe,Chia‐Jen Liu,Antonio Sacco,Daisy Huynh,Yu‐Tzu Tai,Michael Robbins,Jamil Azzi,Irene M. Ghobrial	70
10	SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads 2018 ·Clinical Cancer Research ·Krista Kinneer,John Meekin,Arnaud Tiberghien,Yu‐Tzu Tai,Sandrina Phipps,Christine Mione Kiefer,Marlon C. Rebelatto,Nazzareno Dimasi,Alyssa Moriarty,Kyriakos P. Papadopoulos,Sriram Sridhar,Stephen J. Gregson,Michael J. Wick,Luke A. Masterson,Kenneth C. Anderson,Ronald Herbst,Philip W. Howard,David A. Tice	58
11	Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma 2017 ·Clinical Cancer Research ·M. Sagawa,Hiroto Ohguchi,Takeshi Harada,Mehmet Samur,Yu‐Tzu Tai,Nikhil C. Munshi,Masahiro Kizaki,Teru Hideshima,Kenneth C. Anderson	30
12	Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function 2017 ·Blood ·Matthew Ho,Jiye Liu,Alireza Kalbasi,Takeshi Harada,Teru Hideshima,Paul Dowling,Yu‐Tzu Tai,Li Zhang,Kenneth Wen,Ralph Mazitschek,Amanda McCann,Kenneth C. Anderson,Peter O’Gorman,Giada Bianchi	2
13	Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma 2017 ·Blood ·Tommaso Perini,Raphaël Szalat,Mariateresa Fulciniti,Mehmet Samur,Michael Lopez,Puru Nanjappa,Kenneth Wen,Na Li,Yan Xu,Yu‐Tzu Tai,Masood A. Shammas,Kenneth C. Anderson,Fabio Ciceri,Nikhil Munshi	1
14	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 2015 ·Cancer Discovery ·Francesca Cottini,Teru Hideshima,Rikio Suzuki,Yu‐Tzu Tai,Giampaolo Bianchini,Paul G. Richardson,Kenneth C. Anderson,Giovanni Tonon	87
15	Targeting the miR-221–222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma 2015 ·Cancer Research ·Jianjun Zhao,(unknown),Yiguo Hu,Jianhong Lin,Zhongqiu Wang,Meng Jiang,Ming Chen,Xujun Wang,Yue Kang,Yangsheng Zhou,Tríona Ní Chonghaile,Melanie Johncilla,Yu‐Tzu Tai,Jin Q. Cheng,Antony Letai,Nikhil C. Munshi,Kenneth C. Anderson,Ruben D. Carrasco	72
16	miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway 2014 ·Cancer Research ·Jianjun Zhao,Jianhong Lin,Di Zhu,Xujun Wang,Daniel J. Brooks,Ming Chen,(unknown),Kohichi Takada,Bryan Ciccarelli,(unknown),Jianguo Tao,Yu‐Tzu Tai,Steven P. Treon,Geraldine Pinkus,Winston Patrick Kuo,Teru Hideshima,Mary Bouxsein,Nikhil C. Munshi,Kenneth C. Anderson,Ruben D. Carrasco	159
17	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition 2014 ·Cancer Research ·Naoya Mimura,Teru Hideshima,Toshiyasu Shimomura,Rikio Suzuki,Hiroto Ohguchi,(unknown),Shohei Kikuchi,Yasuhiro Yoshida,Francesca Cottini,Jana Jakubı́ková,Diana Cirstea,Güllü Görgün,Jiro Minami,Yu‐Tzu Tai,Paul G. Richardson,Teruhiro Utsugi,Atsushi Iwama,Kenneth C. Anderson	66
18	Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma 2012 ·Clinical Cancer Research ·Claire Fabre,Naoya Mimura,Kathryn Bobb,Sun‐Young Kong,Güllü Görgün,Diana Cirstea,Yiguo Hu,Jiro Minami,Hiroto Ohguchi,Jie Zhang,Jeffrey Meshulam,Ruben D. Carrasco,Yu‐Tzu Tai,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson	66
19	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma 2009 ·Cancer Research ·Jing Zhang,Martin Sattler,Giovanni Tonon,Clemens Grabher,Samir Lababidi,(unknown),Marc S. Raab,Sonia Vallet,Yiming Zhou,(unknown),Teru Hideshima,Yu‐Tzu Tai,Dharminder Chauhan,Kenneth C. Anderson,Klaus Podar	76
20	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma 2007 ·Cancer Research ·Klaus Podar,Marc S. Raab,Giovanni Tonon,Martin Sattler,Daniela Barilá,Jing Zhang,Yu‐Tzu Tai,Hiroshi Yasui,Noopur Raje,Ronald A. DePinho,Teru Hideshima,Dharminder Chauhan,Kenneth C. Anderson	55

About Yu‐Tzu Tai

Yu‐Tzu Tai is a scholar working on Hematology, Oncology and Immunology, having authored 271 papers that have together received 15.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (184 papers), Protein Degradation and Inhibitors (51 papers) and Peptidase Inhibition and Analysis (40 papers). The work is most often cited by research in Hematology (7.1k citations), Oncology (6.6k citations) and Genetics (1.6k citations). Yu‐Tzu Tai has collaborated with scholars based in United States, China and Italy. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Nikhil C. Munshi, Dharminder Chauhan, Paul G. Richardson, Noopur Raje, Klaus Podar, Steven P. Treon, Robert Schlossman and Boris K. Lin. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact